1
|
Parajuli KR, Jung Y, Taichman RS. Abscisic acid signaling through LANCL2 and PPARγ induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells. Oncol Rep 2024; 51:39. [PMID: 38624012 PMCID: PMC10804438 DOI: 10.3892/or.2024.8698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Accepted: 12/12/2023] [Indexed: 04/17/2024] Open
Abstract
Prostate cancer (PCa) is one the most common malignancies in men. The high incidence of bone metastasis years after primary therapy suggests that disseminated tumor cells must become dormant, but maintain their ability to proliferate in the bone marrow. Abscisic acid (ABA) is a stress response molecule best known for its regulation of seed germination, stomal opening, root shoot growth and other stress responses in plants. ABA is also synthesized by mammalian cells and has been linked to human disease. The aim of the present study was to examine the role of ABA in regulating tumor dormancy via signaling through lanthionine synthetase C‑like protein 2 (LANCL2) and peroxisome proliferator activated receptor γ (PPARγ) receptors. ABA signaling in human PCa cell lines was studied using targeted gene knockdown (KD), western blotting, quantitative PCR, cell proliferation, migration, invasion and soft agar assays, as well as co‑culture assays with bone marrow stromal cells. The data demonstrated that ABA signaling increased the expression of p21, p27 and p16, while inhibiting viability, migration, invasion and colony size in a reversable manner without toxicity. ABA also induced p38MAPK activation and NR2F1 signaling. Targeted gene KD of LANCL2 and PPARγ abrogated the cellular responses to ABA. Taken together, these data demonstrate that ABA may induce dormancy in PCa cell lines through LANCL2 and PPARγ signaling, and suggest novel targets to manage metastatic PCa growth.
Collapse
Affiliation(s)
- Keshab Raj Parajuli
- Department of Periodontology, University of Alabama at Birmingham School of Dentistry, Birmingham, AL 35294, USA
| | - Younghun Jung
- Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA
| | - Russell S. Taichman
- Department of Periodontology, University of Alabama at Birmingham School of Dentistry, Birmingham, AL 35294, USA
- Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA
| |
Collapse
|
2
|
Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, Li F, Zhang H, Case R, Murawsky CM, Estes B, Moore GL, Bernett MJ, Muchhal U, Desjarlais JR, Staley BK, Stevens J, Cooke KS, Aeffner F, Thomas O, Stieglmaier J, Lee JL, Coxon A, Bailis JM. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discov 2024; 14:90-103. [PMID: 37861452 DOI: 10.1158/2159-8290.cd-23-0984] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 09/25/2023] [Accepted: 10/03/2023] [Indexed: 10/21/2023]
Abstract
The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in most prostate tumors and at increased levels in metastatic castration-resistant prostate cancer (mCRPC). We developed a STEAP1-targeted XmAb 2+1 T-cell engager (TCE) molecule, AMG 509 (also designated xaluritamig), that is designed to redirect T cells to kill prostate cancer cells that express STEAP1. AMG 509 mediates potent T cell-dependent cytotoxicity of prostate cancer cell lines in vitro and promotes tumor regression in xenograft and syngeneic mouse models of prostate cancer in vivo. The avidity-driven activity of AMG 509 enables selectivity for tumor cells with high STEAP1 expression compared with normal cells. AMG 509 is the first STEAP1 TCE to advance to clinical testing, and we report a case study of a patient with mCRPC who achieved an objective response on AMG 509 treatment. SIGNIFICANCE Immunotherapy in prostate cancer has met with limited success due to the immunosuppressive microenvironment and lack of tumor-specific targets. AMG 509 provides a targeted immunotherapy approach to engage a patient's T cells to kill STEAP1-expressing tumor cells and represents a new treatment option for mCRPC and potentially more broadly for prostate cancer. See related commentary by Hage Chehade et al., p. 20. See related article by Kelly et al., p. 76. This article is featured in Selected Articles from This Issue, p. 5.
Collapse
Affiliation(s)
| | - Cong Li
- Oncology Research, Amgen Research, Amgen Inc., South San Francisco, California
| | - Lingming Liang
- Oncology Research, Amgen Research, Amgen Inc., South San Francisco, California
| | - Jinghui Zhan
- Oncology Research, Amgen Research, Amgen Inc., Thousand Oaks, California
| | - Juan Estrada
- Oncology Research, Amgen Research, Amgen Inc., Thousand Oaks, California
| | - Tao Osgood
- Oncology Research, Amgen Research, Amgen Inc., Thousand Oaks, California
| | - Fei Li
- Structural Biology, Amgen Research, Amgen Inc., South San Francisco, California
| | - Hanzhi Zhang
- Structural Biology, Amgen Research, Amgen Inc., South San Francisco, California
| | - Ryan Case
- Lead Discovery and Characterization, Amgen Research, Amgen Inc., South San Francisco, California
| | | | - Bram Estes
- Therapeutic Discovery, Amgen Research, Thousand Oaks, California
| | | | | | | | | | - Binnaz K Staley
- Oncology Research, Amgen Research, Amgen Inc., South San Francisco, California
| | - Jennitte Stevens
- Therapeutic Discovery, Amgen Research, Thousand Oaks, California
| | - Keegan S Cooke
- Oncology Research, Amgen Research, Amgen Inc., Thousand Oaks, California
| | - Famke Aeffner
- Translational Safety and Bioanalytical Sciences, Amgen Research, Amgen Inc., South San Francisco, California
| | - Oliver Thomas
- Translational Safety and Bioanalytical Sciences, Amgen Research (Munich) GmbH, Munich, Germany
| | - Julia Stieglmaier
- Early Development Oncology, Amgen Research (Munich) GmbH, Munich, Germany
| | - Jae-Lyun Lee
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
| | - Angela Coxon
- Oncology Research, Amgen Research, Amgen Inc., Thousand Oaks, California
| | - Julie M Bailis
- Oncology Research, Amgen Research, Amgen Inc., South San Francisco, California
| |
Collapse
|